

# Adeniyi Olagunju

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5548587/publications.pdf>

Version: 2024-02-01

42  
papers

548  
citations

643344

15  
h-index

799663

21  
g-index

44  
all docs

44  
docs citations

44  
times ranked

728  
citing authors

#	ARTICLE	IF	CITATIONS
1	Validation and Clinical Application of a Liquid Chromatography–Ultraviolet Detection Method to Quantify Dolutegravir in Dried Blood Spots. <i>Therapeutic Drug Monitoring</i> , 2022, 44, 430-437.	1.0	3
2	Comparison of efavirenz levels in blood and hair with pharmacy refills as measures of adherence and predictors of viral suppression among people living with HIV in Nigeria. <i>AIDS Research and Therapy</i> , 2022, 19, .	0.7	1
3	Optimizing Pharmacology Studies in Pregnant and Lactating Women Using Lessons From HIV: A Consensus Statement. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 36-48.	2.3	29
4	Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2021, 22, 3.	0.7	5
5	Associations between efavirenz concentrations, pharmacogenetics and neurocognitive performance in people living with HIV in Nigeria. <i>Aids</i> , 2021, 35, 1919-1927.	1.0	6
6	Mechanistic Modeling of Maternal Lymphoid and Fetal Plasma Antiretroviral Exposure During the Third Trimester. <i>Frontiers in Pediatrics</i> , 2021, 9, 734122.	0.9	4
7	CYP2B6*6 Genotype Specific Differences in Artemether–Lumefantrine Disposition in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 351-360.	1.0	3
8	Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz. <i>Pharmacogenetics and Genomics</i> , 2020, 30, 96-106.	0.7	1
9	Influence of SLCO1B1 polymorphisms on lopinavir C <sub>trough</sub> in Serbian HIV/AIDS patients. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1289-1295.	1.1	5
10	Innovative Approaches for Pharmacology Studies in Pregnant and Lactating Women: A Viewpoint and Lessons from HIV. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1185-1194.	1.6	16
11	Differential Impact of Nevirapine on Artemether-Lumefantrine Pharmacokinetics in Individuals Stratified by CYP2B6 c.516C>T Genotypes. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	4
12	Do genetic variations in proximal tubule transporters influence tenofovir-induced renal dysfunction? An exploratory study in a Ghanaian population. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1267-1271.	1.3	4
13	Pharmacokinetics of HIV therapies in pregnant patients: an update. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 449-461.	1.5	2
14	Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide versus efavirenz as case studies. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 140, 105068.	1.9	17
15	A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	16
16	Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokinetics. <i>Pharmacogenomics</i> , 2019, 20, 217-223.	0.6	4
17	Pharmacogenetics of artemether–lumefantrine influence on nevirapine disposition: Clinically significant drug–drug interaction?. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 540-550.	1.1	6
18	Evaluation of universal versus genotype-guided efavirenz dose reduction in pregnant women using population pharmacokinetic modelling. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 165-172.	1.3	8

#	ARTICLE	IF	CITATIONS
19	Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African motherâ€“infant pairs. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1013-1019.	1.3	30
20	Effect of Pregnancy on the Pharmacokinetic Interaction between Efavirenz and Lumefantrine in HIV-Malaria Coinfection. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	9
21	The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 529-536.	2.3	28
22	Development, validation and clinical application of a method for the simultaneous quantification of lamivudine, emtricitabine and tenofovir in dried blood and dried breast milk spots using LCâ€“MS/MS. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1060, 300-307.	1.2	23
23	Quality of artemisinin-based antimalarial drugs marketed in Nigeria. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2017, 111, 90-96.	0.7	8
24	Pregnancy affects nevirapine pharmacokinetics. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 381-389.	0.7	10
25	Pharmacogenetics of nevirapine excretion into breast milk and infantsâ€™ exposure through breast milk versus postexposure prophylaxis. <i>Pharmacogenomics</i> , 2016, 17, 891-906.	0.6	5
26	The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 185-198.	1.1	28
27	Pharmacogenetics of pregnancyâ€“induced changes in efavirenz pharmacokinetics. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 298-306.	2.3	39
28	Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2816-2822.	1.3	21
29	Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study. <i>Clinical Infectious Diseases</i> , 2015, 61, 453-463.	2.9	32
30	A Validated Method for Quantification of Efavirenz in Dried Blood Spots Using High-Performance Liquid Chromatographyâ€“Mass Spectrometry. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 220-228.	1.0	28
31	Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 555-561.	1.3	35
32	Class-specific relative genetic contribution for key antiretroviral drugs. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 3074-3079.	1.3	11
33	CYP2B6 516G>T (rs3745274) and Smoking Status Are Associated With Efavirenz Plasma Concentration in a Serbian Cohort of HIV Patients. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 734-738.	1.0	10
34	CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 459-463.	0.7	21
35	Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz. <i>In Silico Pharmacology</i> , 2013, 1, 4.	1.8	26
36	Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective. <i>Future Virology</i> , 2013, 8, 871-890.	0.9	10

#	ARTICLE	IF	CITATIONS
37	Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding. <i>Pharmacogenomics</i> , 2012, 13, 1501-1522.	0.6	23
38	Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocced swabs using liquid chromatography tandem mass spectrometry. <i>Wellcome Open Research</i> , 0, 6, 246.	0.9	1
39	Physiologically-based pharmacokinetic modelling of infant exposure to efavirenz through breastfeeding. <i>AAS Open Research</i> , 0, 1, 16.	1.5	11
40	Viral and antiretroviral dynamics in HIV mother-to-child transmission fluids (VADICT) – Protocol and data analysis plan for a cohort study. <i>Wellcome Open Research</i> , 0, 4, 34.	0.9	4
41	Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocced swabs using liquid chromatography tandem mass spectrometry. <i>Wellcome Open Research</i> , 0, 6, 246.	0.9	0
42	Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocced swabs using liquid chromatography tandem mass spectrometry. <i>Wellcome Open Research</i> , 0, 6, 246.	0.9	1